Free Newsletter
Foundation invests millions to find MS drug leads
The Myelin Repair Foundation has spent $10 million so far to identify 18 new drug leads for multiple sclerosis. The non-profit foundation says it plans to roll out the two best leads to pharma companies this summer, hoping for a licensing deal that will swiftly advance a new drug for MS.
The Foundation is helping blaze a path in new drug research, taking millions of dollars in donations and advancing experimental new therapies to the point that a drug company would want to in-license them for commercial development. And the Foundation is prepared to take a smaller payback in exchange for a faster development path.
- check out the report in the San Francisco Chronicle
Related Articles:
Natural protein used to combat multiple sclerosis. Report
Mass spectrometry helps ID two MS drugs. Report
Antibody stimulates natural repair of MS damage. Report
Comments
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: